A Phase 3 interventional study of Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®) and Latanoprost ophthalmic solution 0.005% (XALATAN®) in Open-angle Glaucoma and Ocular Hypertension, sponsored by Alcon Research. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-07-24.
Sponsored by Alcon Research (part of Alcon) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing travoprost in Glaucoma, Open-Angle — 2 open to participants now, 3 under way, 1 of them phase 3. Travoprost · Glaucoma, Open-Angle.
Among the 46 studies testing travoprost in Glaucoma, Open-Angle, this one is the 2nd largest by enrollment of the 45 interventional ones that give a count, is one of 8 that started in 2008, is one of 16 in phase 3, and was the 16th registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →2 of the 46 studies testing travoprost in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:
Jonathon Myers · Sites in United States
Ages 18+
Glaukos Corporation · Sites in United States
Ages 45+
By country, each count listing its studies:
Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 8 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 726 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 135 across the 45 interventional studies. Of the 43 that completed or were terminated, 23 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 46 have an industry lead sponsor. The 10 most frequent:
This study is registered under Alcon Research, one of the names counted as Alcon. Under that name alone:
Alcon Research is the lead sponsor of 624 studies on the registry; 9 are open to participants now.
Of its 112 completed or terminated interventional studies of FDA-regulated products, 102 (91%) have results posted.
126 studies in Glaucoma, Open-Angle by Alcon: 1 open now, 1 under way, none of them phase 3. Of 121 finished, 58 (48%) have results posted.
Among the 126 studies in Glaucoma, Open-Angle by Alcon, this one is the 9th largest by enrollment of the 112 interventional ones that give a count, is one of 15 that started in 2008, is one of 43 in phase 3, and was the 41st registered.
Alcon’s Glaucoma, Open-Angle studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 46 studies testing travoprost in Glaucoma, Open-Angle, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Alcon’s 126 in Glaucoma, Open-Angle:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to compare two ophthalmic solutions in patients with open-angle glaucoma or ocular hypertension.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One drop self-administered in the study eye(s) once daily for 90 days
Drug: Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)
One drop self-administered in the study eye(s) once daily for 90 days
Drug: Latanoprost ophthalmic solution 0.005% (XALATAN®)
Drug page: Travoprost
Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as travoprost.
Also known as: TRAVATAN Z®
Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as latanprost.
Also known as: XALATAN®
Mean Change at Day 90 From Baseline (Day 0) in Ocular Surface Disease Index (OSDI) Score
The OSDI is a 12-question validated questionnaire (resultant overall 0-100 point score) used to measure ocular symptoms, visual function and environmental factors that may affect a patient's vision, where 0 = normal and 100 = severe. The OSDI questionnaire was administered at both visits and completed by the patient with no assistance from the office staff, physician, or anyone else. The baseline OSDI score was subtracted from the 90-day OSDI score and reported as change. A negative number represents a perceived improvement in ocular health.
Time frame: Baseline, Day 90
Percentage of Patients With Corneal Fluorescein Staining Score = 0
The corneal surface was assessed by the investigator and graded on a scale of 0-3, where 0 = Absent (no staining present) and 3 = Severe (\>50% coverage). Percentage of patients with score = 0 at 90 days was calculated by dividing the number of patients with score = 0 by the total number of patients analyzed.
Time frame: Day 90
Patients were recruited from 70 US study centers. Eligible patients having a diagnosis of open-angle glaucoma or ocular hypertension and on XALATAN® monotherapy for at least one month immediately prior to Visit 1 were enrolled.
| Milestone | Travoprost | Latanoprost |
|---|---|---|
| Started | 363 | 363 |
| Completed | 342 | 328 |
| Not completed | 21 | 35 |
| Withdrew: Adverse event | 12 | 10 |
| Withdrew: Lost to follow-up | 1 | 4 |
| Withdrew: Withdrawal by subject | 0 | 9 |
| Withdrew: Protocol violation | 6 | 7 |
| Withdrew: Noncompliance | 1 | 2 |
| Withdrew: Other not specified | 1 | 3 |
The OSDI is a 12-question validated questionnaire (resultant overall 0-100 point score) used to measure ocular symptoms, visual function and environmental factors that may affect a patient's vision, where 0 = normal and 100 = severe. The OSDI questionnaire was administered at both visits and completed by the patient with no assistance from the office staff, physician, or anyone else. The baseline OSDI score was subtracted from the 90-day OSDI score and reported as change. A negative number represents a perceived improvement in ocular health.
| Units on a scale | Travoprost | Latanoprost |
|---|---|---|
| Mean Change at Day 90 From Baseline (Day 0) in Ocular Surface Disease Index (OSDI) Score | -11.3 ± 0.9 | -11.4 ± 1.0 |
The corneal surface was assessed by the investigator and graded on a scale of 0-3, where 0 = Absent (no staining present) and 3 = Severe (\>50% coverage). Percentage of patients with score = 0 at 90 days was calculated by dividing the number of patients with score = 0 by the total number of patients analyzed.
| percentage of patients | Travoprost | Latanoprost |
|---|---|---|
| Percentage of Patients With Corneal Fluorescein Staining Score = 0 | 37.1 | 40.0 |
Collected over Adverse events were collected for the duration of the study: 03 July 2008 to 26 May 2009.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Travoprost | — | 5/363 (1.4%) | 0/363 (0%) |
| Latanoprost | — | 7/363 (1.9%) | 0/363 (0%) |
| Event | Travoprost | Latanoprost |
|---|---|---|
| Abdominal PainGastrointestinal disorders | 0/363 | 2/363 |
| Coronary Artery OcclusionCardiac disorders | 1/363 | 0/363 |
| Gastroesophageal Reflux DiseaseGastrointestinal disorders | 1/363 | 0/363 |
| HyponatraemiaMetabolism and nutrition disorders | 1/363 | 0/363 |
| Back painMusculoskeletal and connective tissue disorders | 1/363 | 0/363 |
| ConvulsionNervous system disorders | 1/363 | 0/363 |
| Atrial FibrillationCardiac disorders | 0/363 | 1/363 |
| BrachycardiaCardiac disorders | 0/363 | 1/363 |
| Coronary Artery DiseaseCardiac disorders | 0/363 | 1/363 |
| Intestinal ObstructionGastrointestinal disorders | 0/363 | 1/363 |
| Age Continuous(years) | Travoprost | Latanoprost | Total |
|---|---|---|---|
| Mean | 67.1 ± 11.0 | 67.8 ± 10.8 | 67.5 ± 10.9 |
| Sex: Female, Male(Participants) | Travoprost | Latanoprost | Total |
|---|---|---|---|
| Female | 211 | 230 | 441 |
| Male | 132 | 105 | 237 |
No study locations are listed for this record.
The record gives a start of Jul 2008, a primary completion of May 2009 and a completion of May 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2012, 3 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Travoprost